Healthcare / Medical DevicesTSXV
$0.30
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-1.1M · quality 61.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$18M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-262.8%
↓Gross Margin
64.6%
↑Debt/Equity
0.75
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.2%
FCF CAGR
—
FCF margin
-137.9%
FCF / Net income
0.72x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $886467.0 · net income $-1.7M · FCF $-1.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $886467.00 | $886467.00 | $1.0M | $829700.00 | $699092.00 |
| Net Income | $-1.7M | $-1.7M | $-1.2M | $-1.4M | $-4.9M |
| EBITDA | $-1.6M | $-1.6M | $-1.1M | $-1.3M | $-4.7M |
| EPS | -0.03 | -0.03 | -0.03 | -0.04 | -0.14 |
| Gross Margin | 64.6% | 64.6% | 68.1% | 62.0% | 62.2% |
| Operating Margin | -186.6% | -186.6% | -108.9% | -171.5% | -341.8% |
| Net Margin | -190.7% | -190.7% | -112.8% | -173.0% | -695.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.75 | 0.75 | -1.46 | -1.15 | 2.18 |
| Current Ratio | 1.34 | 1.34 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.2M | $-1.2M | $-683183.00 | $-1.1M | $-1.6M |
| Returns | |||||
| ROE | -262.8% | -262.8% | 265.9% | 274.8% | -1454.4% |
| Valuation | |||||
| P/B | 23.84 | 23.84 | — | — | 12.68 |
| Growth & Yield | |||||
| Revenue Growth | -15.4% | -15.4% | 26.3% | 18.7% | — |
| EPS Growth | 0.0% | 0.0% | 25.0% | 71.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+30.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.03 → -0.03
Residual
+30.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.